JPWO2022107853A1 - - Google Patents

Info

Publication number
JPWO2022107853A1
JPWO2022107853A1 JP2022563827A JP2022563827A JPWO2022107853A1 JP WO2022107853 A1 JPWO2022107853 A1 JP WO2022107853A1 JP 2022563827 A JP2022563827 A JP 2022563827A JP 2022563827 A JP2022563827 A JP 2022563827A JP WO2022107853 A1 JPWO2022107853 A1 JP WO2022107853A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022563827A
Other languages
Japanese (ja)
Other versions
JPWO2022107853A5 (cg-RX-API-DMAC7.html
JP7857666B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022107853A1 publication Critical patent/JPWO2022107853A1/ja
Publication of JPWO2022107853A5 publication Critical patent/JPWO2022107853A5/ja
Application granted granted Critical
Publication of JP7857666B2 publication Critical patent/JP7857666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022563827A 2020-11-19 2021-11-18 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療 Active JP7857666B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020192844 2020-11-19
JP2020192844 2020-11-19
JP2021145795 2021-09-07
JP2021145795 2021-09-07
PCT/JP2021/042463 WO2022107853A1 (ja) 2020-11-19 2021-11-18 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療

Publications (3)

Publication Number Publication Date
JPWO2022107853A1 true JPWO2022107853A1 (cg-RX-API-DMAC7.html) 2022-05-27
JPWO2022107853A5 JPWO2022107853A5 (cg-RX-API-DMAC7.html) 2023-10-24
JP7857666B2 JP7857666B2 (ja) 2026-05-13

Family

ID=81707991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563827A Active JP7857666B2 (ja) 2020-11-19 2021-11-18 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療

Country Status (4)

Country Link
US (1) US20230414718A1 (cg-RX-API-DMAC7.html)
EP (1) EP4249003A4 (cg-RX-API-DMAC7.html)
JP (1) JP7857666B2 (cg-RX-API-DMAC7.html)
WO (1) WO2022107853A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6711495B1 (ja) 2019-05-27 2020-06-17 株式会社ナイスリー 車両用盗難防止装置
JP7040806B2 (ja) 2020-03-17 2022-03-23 株式会社オリンピア 遊技機

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KAGAWA, TOMOYO ET AL.: "Hepatocyte Growth Factor Gene Therapy Slows Down the Progression of Diabetic Nephropathy in db/db Mi", NEPHRON PHYSIOLOGY, vol. 102, JPN6021051233, 2006, pages 92 - 102, ISSN: 0005732714 *
LEE, HYE-JEONG ET AL.: "Prevention of Diabetes Using Adenoviral Mediated Hepatocyte Growth Factor Gene Transfer In Mice", KOREAN J PHYSIOL PHARMACOL, vol. 7, JPN6021051240, 2003, pages 261 - 266, ISSN: 0005732710 *
LI, YIWEN ET AL.: "Postinfarction Treatment With an Adenoviral Vector Expressing Hepatocyte Growth Factor Relieves Chro", CIRCULATION, vol. 107, no. 19, JPN6021051237, 2003, pages 2499 - 2506, ISSN: 0005732713 *
MATSUDA, ERIKO ET AL.: "Safe and low-dose but therapeutically effective adenovirus-mediated hepatocyte growth factor gene th", LIFE SCIENCES, vol. 268, no. 119014, JPN6021051230, March 2021 (2021-03-01), pages 1 - 5, ISSN: 0005732715 *
NIWA, HITOSHI ET AL.: "Efficient selection for high-expression transfectants with a novel eukaryotic vector", GENE, vol. 108, no. 2, JPN6021051227, 1991, pages 193 - 200, ISSN: 0005732712 *
PARK, MI-KYOUNG ET AL.: "Adenoviral mediated hepatocyte growth factor gene attenuates hyperglycemia and beta cell destruction", EXPERIMENTAL AND MOLECULAR MEDICINE, vol. 35, no. 6, JPN6021051242, 2003, pages 494 - 500, ISSN: 0005732709 *
中野正和 ほか: "アデノウイルスベクターによる遺伝子治療", ウイルス, vol. 53, no. 2, JPN6021051239, 2003, pages 147 - 153, ISSN: 0005732711 *

Also Published As

Publication number Publication date
WO2022107853A1 (ja) 2022-05-27
EP4249003A4 (en) 2024-10-23
US20230414718A1 (en) 2023-12-28
JP7857666B2 (ja) 2026-05-13
EP4249003A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
BR112022024743A2 (cg-RX-API-DMAC7.html)
BR112023014792B1 (pt) Corrediça dividida, e, conjunto de corrediças de extremidade
BR112022022269B1 (pt) Dispositivos acústicos
CN306876492S (zh) 箱式风机(粮仓专用)
CN305907559S (zh) 一体化筒灯(固定式)
CN305597509S (zh) 玩具饰品
CN305617557S (zh) 手链(圆梦熊猫)
CN305613682S (zh) 壁灯
CN305628735S (zh) 打蛋机(1)
CN305602695S (zh) 花箱(1)
CN305614184S (zh) 宠物服饰(182)
CN305626517S (zh) 手机屏幕放大器
CN305611856S (zh) 橡皮(太空飞机1号)
CN305594352S (zh) 电动自行车
CN305614395S (zh) 内衣(98010)
CN305564119S (zh) 板凳(北极熊)
CN305622705S (zh) 壶(铁釉鱼跃)
CN305563696S (zh) 药丸收纳包
CN305621947S (zh) 餐椅(Mook)
CN305611673S (zh) 稳定云台(大型多轴360度无线遥控)
CN305543572S (zh) 平衡车
CN305549728S (zh) 杯用茶隔(aa059)
CN305605105S (zh) 饮水机
CN305554891S (zh) 型材
CN305552392S (zh) 收音机

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20230407

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260420

R150 Certificate of patent or registration of utility model

Ref document number: 7857666

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150